Nada S Aboelella

6PUBLICATIONS
32CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer cell biologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 11, 2026
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.

|Apr 26, 2026
Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes.

|May 29, 2024
Venetoclax Induces BCL-2-Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti-PD-1 Checkpoint Blockade.

Rosy Liao, Jocelyn Y Hsu, Nada S Aboelella

|Jul 26, 2022
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy.

Nada S Aboelella, Caitlin Brandle, Ogacheko Okoko

|Mar 06, 2021
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy.

Nada S Aboelella, Caitlin Brandle, Timothy Kim

|Oct 31, 2020
Persistent STAT5 activation reprograms the epigenetic landscape in CD4+ T cells to drive polyfunctionality and antitumor immunity.

Zhi-Chun Ding, Huidong Shi, Nada S Aboelella

Pageof 1

Frequent Collaborators

3 joint publications

James L LaBelle

2 joint publications

Zhi-Chun Ding

2 joint publications

Peter A Riedell

2 joint publications

Jun Huang